Global & Disaster Medicine» Blog Archive » Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said the FDA has cleared the emergency use of its therapy to treat acute radiation exposure in a nuclear event.

Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said the FDA has cleared the emergency use of its therapy to treat acute radiation exposure in a nuclear event.

May 2nd, 2018

“…..Pluristem said it will start preparations to keep an emergency stock of PLX-R18 on hand for use in such events.

Full approval of the drug will depend on the results of a Phase III clinical trial…..”

This entry was posted on Wednesday, May 2nd, 2018 at 3:58 am and is filed under Nuclear-Radiation-Contamination .
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Global & Disaster Medicine

Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said the FDA has cleared the emergency use of its therapy to treat acute radiation exposure in a nuclear event.

Categories

Recent Posts

Archives

Admin